10-K: Vyome Holdings Reports FY25 Losses, Advances Key Drug Candidates

Vyome Holdings, Inc. reported a significant net loss for fiscal year 2025, while advancing its lead drug candidate VT-1953 for malignant fungating wounds and outlining plans for future clinical trials and capital raises.

Summary

• Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.) completed a reverse merger with Vyome Therapeutics, Inc. on August 15, 2025, and was subsequently renamed.
• The company is a clinical-stage specialty pharmaceutical company focusing on immune-inflammatory and rare diseases, leveraging a US-India innovation corridor.
• Net loss for the year ended December 31, 2025, was $10,477,713, significantly higher than $1,447,461 in 2024.
• Revenue for 2025 was $319,714, primarily from licensing and milestone fees for Luliconazole and royalties from Sun Pharma in India.
• Research and development expenses increased to $588,258 in 2025 from $285,391 in 2024, driven by resumed R&D activities post-merger.
• General and administrative expenses rose to $2,365,565 in 2025 from $898,572 in 2024, mainly due to legal, accounting, auditing, and stock-based compensation related to the merger.
• Transactional fees of $7,705,533 were incurred in 2025, including $5.9 million in fair value of shares issued to advisors and $1.8 million in cash payments.
• The lead program, VT-1953, a topical gel for malignant fungating wounds (MFW), showed positive Phase 2 investigator-initiated trial results, significantly reducing malodor (median score improved from 0.5 to 4.0 on a 6-point TELER scale, p=0.0020) and pain (median score reduced from 6.0 to 4.0 on a 10-point VAS scale, p=0.0020) by Day 14.
• VT-1953 also demonstrated a direct anti-inflammatory effect, reducing inflammation by over 60% in preclinical studies, and potent efficacy against a broad range of bacteria commonly colonizing MFW.
• The company plans discussions with the FDA on a pivotal Phase 3 trial design for VT-1953 in the first half of 2026.
• VT-1908, an ophthalmic drops program for steroid-sparing anterior uveitis, is in the Pre-Investigational New Drug (IND) application stage, with plans to enable clinical trials by the second half of 2025 (as stated in the business overview, but still in planning as of March 2026).
• VB-1953, for moderate to severe acne, has completed its Phase 2 clinical trial with positive read-outs and is Phase 3-ready; the company intends to pursue partnerships for its pivotal studies.
• The company commercialized two topical anti-fungal products in India through a licensing agreement with Sun Pharma, though the dandruff product supply agreement was terminated in December 2024.
• Cash and cash equivalents were approximately $4,982,000 as of December 31, 2025, and are projected to fund operations for at least 15 months from the financial statement issuance date (March 17, 2026), meaning until June 2027.
• Material weaknesses in internal control over financial reporting were identified, relating to insufficient accounting resources, lack of comprehensive policies/procedures, and inadequate segregation of duties and IT security controls.
• A new Artificial Intelligence (AI) Committee of the Board was established to evaluate and prioritize AI opportunities in healthcare, biotech, and medtech.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative report. While positive clinical data for VT-1953 and strategic moves like the AI Committee offer future potential, the substantial increase in net losses, significant transactional expenses, and identified material weaknesses in internal controls present immediate financial and operational concerns.

Positives

• VT-1953, the lead program for malignant fungating wounds, demonstrated statistically significant reductions in malodor (median score improved from 0.5 to 4.0 on a 6-point TELER scale, p=0.0020) and pain (median score reduced from 6.0 to 4.0 on a 10-point VAS scale, p=0.0020) by Day 14 in a Phase 2 investigator-initiated trial.
• VT-1953 was well-tolerated in clinical trials with negligible local skin reactions and minimal systemic exposure, supporting its safety profile.
• VB-1953 for inflammatory acne showed significant reductions in inflammatory lesions (>70% reduction with BID dosing at 12 weeks) and improved IGA scores in Phase 2 studies, including in patients with clindamycin-resistant bacteria.
• The company successfully completed a reverse merger and private placement offering, raising approximately $6.6 million, and has access to an ATM facility, raising an additional $1.3 million by Dec 31, 2025, and $5.29 million by March 17, 2026.
• A new Artificial Intelligence (AI) Committee of the Board has been established, indicating a strategic focus on leveraging AI in healthcare and biotech.
• The company has a robust intellectual property portfolio with patent protection for key programs extending until 2034 and in some cases until 2043.

Negatives

• The company incurred a significant net loss of $10,477,713 for the year ended December 31, 2025, a substantial increase from $1,447,461 in 2024.
• Operating expenses increased dramatically to $10,671,341 in 2025 from $1,201,310 in 2024, largely due to transactional fees related to the merger.
• The company has a limited operating history and has not yet commercialized any product from its biotechnology segment, relying on a single customer (Sun Pharma) for substantially all pharmaceutical segment revenue.
• The licensing and marketing agreement for dandruff products with Sun Pharma was terminated in December 2024, reducing a revenue stream.
• Material weaknesses in internal control over financial reporting were identified, including insufficient accounting resources, lack of comprehensive policies, inadequate segregation of duties, and IT security risks.
• The company will need substantial additional funding beyond June 2027 to complete clinical trials and pursue its growth strategy, with no guarantee of obtaining it on acceptable terms.
• The ability to use net operating loss (NOL) carryforwards is substantially limited due to ownership changes, with only approximately $400,000 of the inherited $230 million federal NOLs usable annually.

Risks

• Limited operating history and no product commercialization from the biotechnology segment, leading to expected significant losses for the foreseeable future.
• Substantial dependence on the success of VT-1953 and VT-1908, with anticipated clinical trials potentially facing delays, difficulties in patient enrollment, or failure to meet regulatory requirements.
• Results from preclinical testing and early clinical trials may not be predictive of success in later-stage clinical trials.
• Potential for VT-1953 and VT-1908 to have undesirable safety profiles or unexpected characteristics that could prevent regulatory approval or limit commercial potential.
• Exposure to product liability claims, which could be expensive, divert management's attention, and harm reputation, with no guarantee of adequate product liability insurance.
• Substantial competition from major pharmaceutical and biotechnology companies with significantly greater financial, technical, and human resources.
• Reliance on third parties (CROs, CMOs, consultants) for preclinical studies, clinical trials, and manufacturing, with risks of failure to meet obligations, deadlines, or quality standards.
• Internal computer systems or those of third parties may fail or suffer security/data privacy breaches, leading to costs, revenue loss, liabilities, and operational disruption.
• Generating all current revenues from one customer (Sun Pharma), with the loss of this business significantly harming revenues and overall business.
• Difficulties in managing organizational growth due to limited financial resources and management experience.
• Uncertainty in protecting patents and other proprietary rights, with risks of challenges to validity, unenforceability, or infringement by competitors.
• Inadequate patent terms or failure to obtain patent term extensions could limit competitive position.
• Complex, time-consuming, and unpredictable regulatory approval processes by the FDA, EMA, and other authorities, potentially delaying or preventing commercialization.
• Extensive ongoing regulatory obligations and continued review post-approval, leading to significant additional expense and potential penalties for non-compliance.
• Unfavorable pricing regulations and/or third-party coverage and reimbursement policies may prevent offering products at competitive prices.
• Risks related to privacy, data protection, information security, and consumer protection laws across different markets, with potential for fines, litigation, and reputational damage for non-compliance.
• Lack of a formal compliance program consistent with federal agencies' guidance on corporate compliance programs, increasing risk of undetected regulatory violations.
• Political changes in the Government of India could adversely affect economic conditions and the company's business in India.
• The Indian subsidiary may not be in compliance with local laws, potentially facing penalties and fines.

Future Outlook

The company plans to have discussions with the FDA on a pivotal Phase 3 trial design for VT-1953 in the first half of 2026. It also anticipates initiating IND-enabling studies followed by Phase 1 and Phase 2 trials for VT-1908. For VB-1953, the company will pursue partnerships for pivotal Phase 3 studies. Substantial additional funding will be required to complete these trials and support growth beyond June 2027. The company intends to continue leveraging its US-India footprint for strategic and commercial opportunities, including seeking partnerships in Europe, Canada, and other markets while retaining the US market for commercialization.

Management Comments

• Management believes the US and India relations are seeing a transformation driven by geopolitical and economic alignments, and Vyome intends to build its platform by taking advantage of this.
• Management believes VT-1953's potential to treat symptoms of malignant fungating wounds can be transformative for cancer patients and their caregivers.
• Management believes the preclinical toxicity studies are sufficient to support the use of VT-1953 at the 200mg/kg dose planned for clinical studies.
• Clinical investigators noted that the primary efficacy endpoint was achieved for VB-1953 in Phase 2 acne trials, with statistically significant reductions in inflammatory lesion counts, and the safety profile was comparable to vehicle.
• Management aims to initiate a pivotal study to test the efficacy of VT-1953 in alleviating malodor associated with MFW, with Phase 2 results informing the Phase 3 design.
• Management believes existing cash, along with proceeds from recent financing, will fund operating expenses and capital expenditure requirements for at least 15 months (until June 2027).

Industry Context

StockSavvy.ai notes that Vyome Holdings operates in the highly competitive biotechnology and pharmaceutical industries, characterized by rapidly advancing technologies and intense competition. The company's strategy of repurposing FDA-approved active molecules for rare (orphan) immune-inflammatory conditions aims to disrupt the expensive classical drug development model by reducing development time, toxicity risks, and clinical development costs. This approach aligns with a growing trend in the industry to seek efficiencies and leverage existing knowledge. The focus on the US-India innovation corridor is a unique strategic advantage, particularly in light of geopolitical shifts and capital outflow from China, positioning the company to tap into a large talent pool and cost-efficient development. The establishment of an AI Committee also reflects a broader industry trend towards integrating artificial intelligence into drug discovery and development to enhance efficiency and innovation.

Comparison to Industry Standards

• The company's strategy of targeting orphan indications with repurposed drugs is consistent with regulatory incentives under the Orphan Drug Act, which provides benefits like tax credits, user-fee waivers, and seven years of market exclusivity in the U.S.
• Pivotal trials for orphan drugs, as cited in the Journal of American Medical Association (JAMA), are often smaller (median 96 patients vs. 290 for non-orphan drugs) and may use non-randomized, unblinded designs and surrogate endpoints, which the company aims to leverage for VT-1953.
• Examples of orphan drugs approved based on small patient populations include Carbaglu (fewer than 20 patients), VPRIV (25 patients), Myozyme (18 patients), and Ceprotin (18 patients), providing a benchmark for the feasibility of VT-1953's development path.
• The company's preclinical data for VT-1953 shows it is more potent than metronidazole (currently used off-label for MFW) against anaerobes (4X to 8X more potent) and effective against aerobes, which metronidazole does not target, suggesting a superior therapeutic profile compared to current suboptimal treatments.
• The market potential for VT-1953 in MFW is estimated at $2.2 billion annually in the U.S., with potential peak annual U.S. net sales of $600 million, and a risk-adjusted asset value of $455 million, which could increase to $1 billion upon Phase 3 completion and approval, indicating a substantial market opportunity for an orphan drug.
• The addressable market for VT-1908 in uveitis is estimated at $2.6 billion by 2032, with broader ophthalmology indications like dry eye disease ($13 billion by 2030) and post-cataract surgery inflammation ($8.78 billion by 2033) representing significant growth opportunities, aligning with large and growing markets in the pharmaceutical sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation and is not aware of any pending or threatened litigation that could have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Dr. Shiladitya Sengupta, a director, has a consulting agreement with Vyome Therapeutics, Inc. (VTI) for $100,000 per annum, and received stock awards with an estimated fair value of $151,939 in 2024.
• The company incurred consultancy charges to certain members of the Board of Directors, amounting to approximately $100,000 for each of the years ended December 31, 2025 and 2024, with $200,000 outstanding as of December 31, 2025.
• Compensation expenses to the Chief Executive Officer (Venkat Nelabhotla) amounted to approximately $260,000 for each of the years ended December 31, 2025 and 2024, with $323,066 outstanding as of December 31, 2025.
• Certain directors provided short-term advances to the company, amounting to approximately $5,000 at December 31, 2025, and $15,000 at December 31, 2024.
• In February 2026, a newly formed subsidiary of LICH (LICH sub) purchased a note receivable from an investor in Humanyze, an AI company. This investor is also an investor in Vyome Holdings, and a principal of this investor is a member of both Humanyze and Vyome's Board of Directors (Krishna Gupta).

Stakeholder Impact

• **Shareholders:** Experienced significant dilution from future equity offerings and exercise of put/call options. The trading price of common stock has been volatile and is likely to remain so. The company does not expect to pay cash dividends in the foreseeable future, limiting returns to capital appreciation.
• **Employees:** The company undertook a cost reduction plan and reorganization, including a significant workforce reduction, which could lead to loss of institutional knowledge, reduced morale, and difficulties in operations.
• **Patients:** Potential for new therapeutic solutions for unmet medical needs in immune-inflammatory and rare diseases, particularly for malignant fungating wounds and uveitis, could significantly improve quality of life.
• **Customers (Sun Pharma):** The termination of the dandruff product supply agreement with Sun Pharma reduces a revenue stream, highlighting reliance on a single major customer for pharmaceutical segment revenue.
• **Creditors:** The conversion of convertible notes and debt into equity instruments in connection with the merger has altered the company's debt structure.

Next Steps

• Conduct discussions with the FDA on a pivotal Phase 3 trial design for VT-1953 in the first half of 2026.
• Initiate IND-enabling studies followed by Phases 1 and 2 for VT-1908.
• Seek partnerships for pivotal Phase 3 studies of VB-1953 for inflammatory acne.
• Continue to strengthen the intellectual property portfolio by filing additional patents.
• Actively explore and evaluate potential value-creating partnering opportunities for existing pipeline and MRT platform.
• Evaluate additional assets and complementary technologies for in-licensing.
• Implement and develop managerial, operational, and financial systems to manage anticipated growth.
• Remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for Vyome Holdings. While the company faces significant financial challenges, including substantial net losses and identified material weaknesses in internal controls, the positive Phase 2 clinical trial results for VT-1953 in malignant fungating wounds are promising for an orphan drug designation. The strategic focus on the US-India innovation corridor and the establishment of an AI Committee indicate forward-looking growth initiatives. However, the early stage of its biotechnology pipeline, reliance on third parties, and the need for substantial future capital raises introduce considerable risk. Investors should monitor progress in clinical trials, regulatory approvals, and the company's ability to secure additional funding and remediate internal control issues before considering a stronger position.

Keywords

Biotechnology, Pharmaceuticals, Clinical-stage, Orphan drug, Malignant fungating wounds, Uveitis, Acne, Drug development, SEC filing, 10-K, Immune-inflammatory diseases, VT-1953, VT-1908, VB-1953, Sun Pharma, Intellectual property, FDA approval, Clinical trials, Capital raise, Corporate governance, Internal controls, AI Committee